PMC:7161517 / 21764-22163 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T129","span":{"begin":85,"end":103},"obj":"Body_part"},{"id":"T130","span":{"begin":268,"end":274},"obj":"Body_part"},{"id":"T131","span":{"begin":275,"end":284},"obj":"Body_part"}],"attributes":[{"id":"A129","pred":"fma_id","subj":"T129","obj":"http://purl.org/sig/ont/fma/fma66326"},{"id":"A130","pred":"fma_id","subj":"T130","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A131","pred":"fma_id","subj":"T131","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T66","span":{"begin":85,"end":103},"obj":"Body_part"}],"attributes":[{"id":"A66","pred":"uberon_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/UBERON_0002012"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T89","span":{"begin":85,"end":116},"obj":"Disease"},{"id":"T91","span":{"begin":104,"end":116},"obj":"Disease"}],"attributes":[{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0015924"},{"id":"A90","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0024533"},{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T215","span":{"begin":79,"end":84},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T216","span":{"begin":85,"end":103},"obj":"http://purl.obolibrary.org/obo/UBERON_0002012"},{"id":"T217","span":{"begin":85,"end":103},"obj":"http://www.ebi.ac.uk/efo/EFO_0001399"},{"id":"T218","span":{"begin":157,"end":165},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T219","span":{"begin":268,"end":274},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T267","span":{"begin":302,"end":315},"obj":"Chemical"}],"attributes":[{"id":"A267","pred":"chebi_id","subj":"T267","obj":"http://purl.obolibrary.org/obo/CHEBI_86267"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T137","span":{"begin":0,"end":171},"obj":"Sentence"},{"id":"T138","span":{"begin":172,"end":399},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":85,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002092"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T759","span":{"begin":79,"end":84},"obj":"SP_6;NCBITaxon:9606"},{"id":"T760","span":{"begin":85,"end":103},"obj":"UBERON:0002012"},{"id":"T761","span":{"begin":152,"end":156},"obj":"G_3;PG_10;PR:000003622"},{"id":"T762","span":{"begin":210,"end":217},"obj":"UBERON:0000948"},{"id":"T763","span":{"begin":268,"end":274},"obj":"UBERON:0001969"},{"id":"T764","span":{"begin":302,"end":315},"obj":"CHEBI:86267;CHEBI:86267"},{"id":"T765","span":{"begin":378,"end":383},"obj":"UBERON:0002113"},{"id":"T89094","span":{"begin":33,"end":38},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T42418","span":{"begin":65,"end":79},"obj":"GO:0010467"},{"id":"T33738","span":{"begin":83,"end":87},"obj":"G_3;PG_10;PR:000003622"},{"id":"T80753","span":{"begin":88,"end":95},"obj":"PR:000036013"},{"id":"T25938","span":{"begin":99,"end":106},"obj":"UBERON:0000948"},{"id":"T79570","span":{"begin":203,"end":213},"obj":"UBERON:0002349"},{"id":"T17295","span":{"begin":231,"end":238},"obj":"UBERON:0000948"},{"id":"T7913","span":{"begin":247,"end":263},"obj":"UBERON:0004535"},{"id":"T31024","span":{"begin":283,"end":289},"obj":"UBERON:0000479"},{"id":"T80939","span":{"begin":338,"end":342},"obj":"G_3;PG_10;PR:000003622"},{"id":"T64668","span":{"begin":343,"end":347},"obj":"PR:000036013"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"950","span":{"begin":152,"end":156},"obj":"Gene"},{"id":"951","span":{"begin":79,"end":84},"obj":"Species"},{"id":"952","span":{"begin":69,"end":75},"obj":"Chemical"},{"id":"953","span":{"begin":187,"end":193},"obj":"Chemical"},{"id":"954","span":{"begin":302,"end":315},"obj":"Chemical"},{"id":"955","span":{"begin":85,"end":116},"obj":"Disease"}],"attributes":[{"id":"A950","pred":"tao:has_database_id","subj":"950","obj":"Gene:59272"},{"id":"A951","pred":"tao:has_database_id","subj":"951","obj":"Tax:9606"},{"id":"A954","pred":"tao:has_database_id","subj":"954","obj":"MESH:C002744"},{"id":"A955","pred":"tao:has_database_id","subj":"955","obj":"MESH:D000081029"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}

{"project":"2_test","denotations":[{"id":"32305401-29903860-55252979","span":{"begin":167,"end":169},"obj":"29903860"},{"id":"32305401-29903860-55252980","span":{"begin":395,"end":397},"obj":"29903860"}],"text":"An additional pilot study (NCT101884051) investigated the effects of rhACE2 in human pulmonary arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion (58)."}